MiR-199a-modified Exosomes from Adipose Tissue-derived Mesenchymal Stem Cells Improve Hepatocellular Carcinoma Chemosensitivity Through MTOR Pathway

Overview

Journal J Exp Clin Cancer Res

Publisher Biomed Central

Specialty Oncology

Date 2020 Jan 4

PMID 31898515

Citations 144

Authors

Guohua Lou

Liang Chen

Caixia Xia

Weina Wang

Jinjin Qi

Aichun Li

Liying Zhao

Zhi Chen

Min Zheng

Yanning Liu

Affiliations

Soon will be listed here.

Abstract

Background: MiR-199a-3p (miR-199a) can enhance the chemosensitivity of hepatocellular carcinoma (HCC). Because of the easy degradation of miRNA by direct infusion, effective vehicle-mediated delivery of miR-199a may represent a new strategy for improving HCC chemotherapy. Considering mesenchymal stem cell (MSC)-derived exosomes as promising natural nanovectors for drug and molecule delivery, we aimed to determine whether exosomes from adipose tissue-derived MSCs (AMSCs) could be used to deliver miR-199a and improve HCC chemosensitivity.

Methods: MiR-199a-modified AMSCs (AMSC-199a) were constructed by miR-199a lentivirus infection and puromycin selection. MiR-199-modified exosomes (AMSC-Exo-199a) were isolated from the supernatant of AMSC-199a and were assessed by transmission electron microscopy, nanoparticle tracking analysis, and flow cytometry analysis. The expression levels of miR-199a in HCC samples, AMSCs, exosomes, and HCC cells were quantified by real-time PCR. The effects of AMSC-Exo-199a on HCC chemosensitivity were determined by cell proliferation and apoptosis assays and by i.v. injection into orthotopic HCC mouse models with doxorubicin treatment. MTOR, p-4EBP1 and p-70S6K levels in HCC cells and tissues were quantified by Western blot.

Results: AMSC-Exo-199a had the classic characteristics of exosomes and could effectively mediate miR-199a delivery to HCC cells. Additionally, AMSC-Exo-199a significantly sensitized HCC cells to doxorubicin by targeting mTOR and subsequently inhibiting the mTOR pathway. Moreover, i.v.-injected AMSC-Exo-199a could distribute to tumor tissue and markedly increased the effect of Dox against HCC in vivo.

Conclusions: AMSC-Exo-199a can be an effective vehicle for miR-199a delivery, and they effectively sensitized HCC to chemotherapeutic agents by targeting mTOR pathway. AMSC-Exo-199a administration may provide a new strategy for improving HCC chemosensitivity.

Citing Articles

Engineered exosomes restore miR-508-5p expression in uterine corpus endometrial carcinoma and reduce tumor progression and metastasis by targeting DLL3.

Li Y, Liu H, Feng J, Tian W, Du J, Zhang L Front Oncol. 2025; 15:1532564.

PMID: 40066092 PMC: 11891050. DOI: 10.3389/fonc.2025.1532564.

Strategies for discovering novel hepatocellular carcinoma biomarkers.

Wu S, Zhu L, Feng X, Wang H, Li F World J Hepatol. 2025; 17(2):101201.

PMID: 40027561 PMC: 11866143. DOI: 10.4254/wjh.v17.i2.101201.

Risk factors of primary liver cancer initiation associated with tumour initiating cell emergence: novel targets for promising preventive therapies.

Brouillet A, Lafdil F eGastroenterology. 2025; 1(1):e100010.

PMID: 39944247 PMC: 11770463. DOI: 10.1136/egastro-2023-100010.

Overcoming drug resistance through extracellular vesicle-based drug delivery system in cancer treatment.

Zheng L, Chang R, Liang B, Wang Y, Zhu Y, Jia Z Cancer Drug Resist. 2025; 7():50.

PMID: 39802949 PMC: 11724354. DOI: 10.20517/cdr.2024.107.

Extracellular vesicles in tumor-adipose tissue crosstalk: key drivers and therapeutic targets in cancer cachexia.

Ramos C, Pires J, Gonzalez E, Garcia-Vallicrosa C, Reis C, Falcon-Perez J Extracell Vesicles Circ Nucl Acids. 2024; 5(3):371-396.

PMID: 39697630 PMC: 11648493. DOI: 10.20517/evcna.2024.36.

References

Cui Y, Wu F, Tian D, Wang T, Lu T, Huang X . miR-199a-3p enhances cisplatin sensitivity of ovarian cancer cells by targeting ITGB8. Oncol Rep. 2018; 39(4):1649-1657. PMC: 5868401. DOI: 10.3892/or.2018.6259. View

Lou G, Dong X, Xia C, Ye B, Yan Q, Wu S . Direct targeting sperm-associated antigen 9 by miR-141 influences hepatocellular carcinoma cell growth and metastasis via JNK pathway. J Exp Clin Cancer Res. 2016; 35:14. PMC: 4721207. DOI: 10.1186/s13046-016-0289-z. View

Zeng B, Shi W, Tan G . MiR-199a/b-3p inhibits gastric cancer cell proliferation via down-regulating PAK4/MEK/ERK signaling pathway. BMC Cancer. 2018; 18(1):34. PMC: 5756398. DOI: 10.1186/s12885-017-3949-2. View

Hua H, Kong Q, Zhang H, Wang J, Luo T, Jiang Y . Targeting mTOR for cancer therapy. J Hematol Oncol. 2019; 12(1):71. PMC: 6612215. DOI: 10.1186/s13045-019-0754-1. View

Yeo R, Lai R, Zhang B, Tan S, Yin Y, Teh B . Mesenchymal stem cell: an efficient mass producer of exosomes for drug delivery. Adv Drug Deliv Rev. 2012; 65(3):336-41. DOI: 10.1016/j.addr.2012.07.001. View

El-Serag H . Hepatocellular carcinoma. N Engl J Med. 2011; 365(12):1118-27. DOI: 10.1056/NEJMra1001683. View

Katakowski M, Buller B, Zheng X, Lu Y, Rogers T, Osobamiro O . Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth. Cancer Lett. 2013; 335(1):201-4. PMC: 3665755. DOI: 10.1016/j.canlet.2013.02.019. View

Wang L, Liu X, Zhou Q, Sui M, Lu Z, Zhou Z . Terminating the criminal collaboration in pancreatic cancer: Nanoparticle-based synergistic therapy for overcoming fibroblast-induced drug resistance. Biomaterials. 2017; 144:105-118. DOI: 10.1016/j.biomaterials.2017.08.002. View

Callegari E, DAbundo L, Guerriero P, Simioni C, Elamin B, Russo M . miR-199a-3p Modulates MTOR and PAK4 Pathways and Inhibits Tumor Growth in a Hepatocellular Carcinoma Transgenic Mouse Model. Mol Ther Nucleic Acids. 2018; 11:485-493. PMC: 5992479. DOI: 10.1016/j.omtn.2018.04.002. View

10.

Carthew R, Sontheimer E . Origins and Mechanisms of miRNAs and siRNAs. Cell. 2009; 136(4):642-55. PMC: 2675692. DOI: 10.1016/j.cell.2009.01.035. View

11.

Ren K, Li T, Zhang W, Ren J, Li Z, Wu G . miR-199a-3p inhibits cell proliferation and induces apoptosis by targeting YAP1, suppressing Jagged1-Notch signaling in human hepatocellular carcinoma. J Biomed Sci. 2016; 23(1):79. PMC: 5103406. DOI: 10.1186/s12929-016-0295-7. View

12.

Peng X, Zhang D, Li Z, Fu M, Liu H . mTOR inhibition sensitizes human hepatocellular carcinoma cells to resminostat. Biochem Biophys Res Commun. 2016; 477(4):556-562. DOI: 10.1016/j.bbrc.2016.06.060. View

13.

Lohitesh K, Chowdhury R, Mukherjee S . Resistance a major hindrance to chemotherapy in hepatocellular carcinoma: an insight. Cancer Cell Int. 2018; 18:44. PMC: 5859782. DOI: 10.1186/s12935-018-0538-7. View

14.

Turato C, Balasso A, Carloni V, Tiribelli C, Mastrotto F, Mazzocca A . New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma. J Control Release. 2017; 268:184-197. DOI: 10.1016/j.jconrel.2017.10.027. View

15.

Munoz J, Bliss S, Greco S, Ramkissoon S, Ligon K, Rameshwar P . Delivery of Functional Anti-miR-9 by Mesenchymal Stem Cell-derived Exosomes to Glioblastoma Multiforme Cells Conferred Chemosensitivity. Mol Ther Nucleic Acids. 2013; 2:e126. PMC: 4027430. DOI: 10.1038/mtna.2013.60. View

16.

Tran P, Xiang D, Tran T, Yin W, Zhang Y, Kong L . Exosomes and Nanoengineering: A Match Made for Precision Therapeutics. Adv Mater. 2019; 32(18):e1904040. DOI: 10.1002/adma.201904040. View

17.

Kim J, Badawi M, Park J, Jiang J, Mo X, Roberts L . Anti-invasion and anti-migration effects of miR-199a-3p in hepatocellular carcinoma are due in part to targeting CD151. Int J Oncol. 2016; 49(5):2037-2045. DOI: 10.3892/ijo.2016.3677. View

18.

Liao W, Du Y, Zhang C, Pan F, Yao Y, Zhang T . Exosomes: The next generation of endogenous nanomaterials for advanced drug delivery and therapy. Acta Biomater. 2019; 86:1-14. DOI: 10.1016/j.actbio.2018.12.045. View

19.

Zhang H, Dou J, Yu Y, Zhao Y, Fan Y, Cheng J . mTOR ATP-competitive inhibitor INK128 inhibits neuroblastoma growth via blocking mTORC signaling. Apoptosis. 2014; 20(1):50-62. PMC: 4593396. DOI: 10.1007/s10495-014-1066-0. View

20.

Hou J, Lin L, Zhou W, Wang Z, Ding G, Dong Q . Identification of miRNomes in human liver and hepatocellular carcinoma reveals miR-199a/b-3p as therapeutic target for hepatocellular carcinoma. Cancer Cell. 2011; 19(2):232-43. DOI: 10.1016/j.ccr.2011.01.001. View